SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-291705
Filing Date
2023-12-08
Accepted
2023-12-08 16:21:00
Documents
12
Period of Report
2023-12-04
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d608194d8k.htm   iXBRL 8-K 22803
  Complete submission text file 0001193125-23-291705.txt   147175

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acrv-20231204.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20231204_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20231204_pre.xml EX-101.PRE 11699
6 EXTRACTED XBRL INSTANCE DOCUMENT d608194d8k_htm.xml XML 3459
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 231475683
SIC: 2834 Pharmaceutical Preparations